An interventional study of Quantum Magnetic and Sham Mode MM Device in Rehabilitation Program, Stroke Rehabilitation and Physical Functional Performance, sponsored by QuantumTX Pte Ltd. Completed at 2 sites in Singapore. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by QuantumTX Pte Ltd · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Stroke with a site in Singapore — 16 open to participants now, 21 under way, 1 of them phase 3. Stroke · Singapore.
Among the 104 studies in Stroke with a site in Singapore, this one is the 39th largest by enrollment of the 86 interventional ones that give a count, is one of 12 that started in 2024, is one of 58 with no phase, and was the 87th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →16 of the 104 studies in Stroke with a site in Singapore are open now. Recruiting first, the newest first:
The Hong Kong Polytechnic University · Sites in Singapore, Hong Kong
Ages 21–79 · Healthy volunteers
Tan Tock Seng Hospital · Sites in Singapore
Ages 21–80
National University of Singapore · Sites in Singapore
Ages 21–65
Mah Shi Min · Sites in Singapore
Ages 21–99
Tan Tock Seng Hospital · Sites in Singapore
Ages 50+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 30 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 15 · Phase 4 7
First in 1998; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 51 across the 86 interventional studies, 300 across the 17 observational. Of the 79 that completed or were terminated, 16 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 104 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with QuantumTX Pte Ltd as lead sponsor.
QuantumTX Pte Ltd has 1 study filed under Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Stroke with a site in Singapore that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06999876National University Health System, SingaporeThe Effect of Combined Transcranial Pulse Current Stimulation (tPCS) and Transcutaneous Electrical Nerve Stimulation (TENS) on Lower Limb Motor Function in Subacute to Chronic Stroke Patients With Hemiplegia (COMPENSATOR-Stroke) | 2026-11-30 |
| NCT06704997Tan Tock Seng HospitalMachine Learning to Predict Factors Affecting Rehabilitation Length of Stay and Healthcare Costs for Neurological Rehabilitation | 2026-12-31 |
| NCT06409351Singapore General HospitalMulti-modal Training Program to Promote Physical Activity After Stroke | 2026-12-31 |
| NCT06073106Tan Tock Seng HospitalTargeting Osteosarcopaenia and Multimorbidity for Frailty Prevention | 2027-01 |
| NCT07122752Tan Tock Seng HospitalFeasibility and Outcomes of 3D-printed External Cranial Orthosis After Craniectomy | 2027-08-29 |
Add all 6 to your calendar (.ics) → With an account.
Among the 104 studies in Stroke with a site in Singapore, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery.
The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at the function outcomes and changes in quality of life of patients after MM therapy, which is more relevant to the clinical practice in stroke recovery.
Based on literature review and previous studies, stroke patients might benefit from MM therapy by enhancing the outcomes in functional mobility and measures of quality of life, so the purpose of this study is to investigate if MM treatment could boost the functional recovery and muscle strength on top of the effects from the conventional physiotherapy.
The findings of this study might improve the medical knowledge on how MM therapy could affect clinical function outcome in post-stroke rehabilitation and provide alternative method to enhance motor recovery.
In this clinical trial, participants will be exposed to MM fields for 10 minutes per week for a maximum of 12 weeks in addition to standard clinical follow-up.
The route of administration, dosage, and frequency are based on studies done in vitro and in vivo models in mice and in adults. At the Swiss Federal Institute of Technology (ETH) in Zurich, the inventors of the MM device were contracted by the Swiss Agency (Bundesamt für Gesundheit, BAG) to test for the safety of diverse PEMF-delivery devices. The MM device was shown to be non-cytotoxic and non-transforming and produces pulsed magnetic fields at flux densities up to 2 mT peak and consists of a privately designed control unit and coil system. For clinical purposes the MM device will be working at less than this value (1.5 mT). Previous data showed enhancement in muscle with only 10 minutes of non-invasive MM fields exposure per week in mice.
In previous human trials, on healthy individuals following ACL-reconstructive surgery, exposure to MM fields showed muscle metabolic improvement and reduced muscle breakdown (measured effects of MM on serum ceramides, lysophosphatidylcholine, TNNT1 and P3NP), myokine upregulation reflecting improved muscle regeneration (measured effects of MM on Follistatin, IGF1, FGF21, IL-6). This was in response to two 10 minutes MM exposures per week on the operated leg. These findings helped to set up the treatment regime for the MM device to impose myogenic effects, including exposure time per session, number of treatment sessions and duration of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
control group receiving the placebo
Device: Sham Mode MM Device
Intervention group receiving MM therapy
Device: Quantum Magnetic
The intervention will be held at the stipulated study sites. Participants in the intervention group will be exposed to active pulse electromagnetic field treatment by a tested device. The active pulse electromagnetic field device does not produce heat or cause any sensation to the tissue which allows the participants to be blinded to the treatment.
Sham sessions help to maintain participant blinding while eliminating the therapeutic electromagnetic field exposure. The sham device mode reproduces the visual and auditory characteristics of active MM treatment, including display screens, indicator lights, operational sounds, and treatment duration timer. However, no therapeutic electromagnetic field is generated. MM devices can be configured to deliver either active treatment or sham treatment through the use of an RFID card reader. RFID cards are pre-programmed and randomised to correspond to either an active or sham session. When the assigned RFID card is tapped on the device, the corresponding treatment protocol is automatically initiated. Therefore double-blinding of both participants and study team / operators / assessors is possible
Safety - Safety profile and Number of participants with treatment-related AEs and SAEs
To assess safety of MM in subacute stroke patients with moderately affected mobility for functional mobility training, assessed through number of participants with treatment-related adverse events, and safety evaluation of the adverse event (AE) profiles.
Time frame: 16 weeks
Mobility - 10-Metre Walk Test
Gait speed assessed by 10-Metre Walk Test, administered by physiotherapist.
Time frame: From baseline to 16 weeks
Mobility - 5 Times Sit To Stand Test
Lower limb strength assessed through the 5TSTS administered by a physiotherapist.
Time frame: From baseline to 16 weeks
Mobility - Timed Up and Go
Dynamic balance assessed through the TUG administered by a physiotherapist.
Time frame: From baseline to 16 weeks
Quality of Life - EuroQoL-5D-5L
EQ-5D-5L is an established tool for assessing the general health status of individuals across a wide array of health conditions and treatments. It measures health outcomes in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-level scale, from no problems (level 1) to extreme problems (level 5), facilitating a comprehensive evaluation of a patient's health-related quality of life. The total score is derived by converting the individual dimension scores into a single summary index value, reflecting the overall health status, with higher scores indicating better health outcomes.
Time frame: From baseline to 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Mar 2026, 23 months.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 23 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.